Trial Profile
An Alemtuzumab-Induction Program with Belatacept, mycophenolate mofetil (MMF) and steroid taper in Kidney Transplantation.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Belatacept (Primary) ; Mycophenolate mofetil; Steroids
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 18 Dec 2015 New trial record
- 31 Jul 2014 Preliminary results presented at the World Transplant Congress 2014